A number similar to what the U.S. has invested would put us back on a competitive pace with them. Seeing what they've done with these funds has really opened my eyes to where we're falling short and what we're capable of.
My sense is that it would be a combination of competition—just letting the best ideas bubble up—as well as perhaps some targeted and specific areas of Canadian strength. For example, we could advance our work in islet biology, in replacement and regeneration, in prevention and in partnership perhaps with organizations like JDRF, where there's a specific interest in type 1 diabetes. We still have a lot to learn about autoimmunity, on beta cells and in clinical trials as well.